Skip to main content

REGENXBIO Inc.

RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001590877

In the last 90 days, REGENXBIO Inc. insiders filed 1 open-market purchase and 0 sales; 165 institutions reported holding it in 13F filings for Q2 2026, worth $504.6M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding REGENXBIO Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of RGNX: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders184172−12
Shares32.9M33.5M+638.6K (+1.9%)
Value$1.12B$1.30B+$180.1M (+16.1%)

New holders (13)

Institutions that held REGENXBIO Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to RGNX in Q2 2021
InstitutionSharesValue% of portfolio
Altium Capital Management LP62,317$2.42M0.56%
Hennion & Walsh Asset Management, Inc.20,312$789.0K0.04%
Amalgamated Bank18,825$731.0K0.01%
Blueshift Asset Management, LLC11,342$441.0K0.02%
Ergoteles LLC7,400$287.0K0.01%
Gyon Technologies Capital Management, LP6,257$243.0K0.08%
Stifel Financial Corp6,239$242.0K0.00%
Virginia Retirement Systems Et Al6,100$237.0K0.00%
Vident Investment Advisory, LLC5,482$213.0K0.01%
STRS Ohio5,400$209.0K0.00%
Fort Sheridan Advisors LLC5,253$204.0K0.07%
Point72 Hong Kong Ltd1,890$73.0K0.01%
Sutton Wealth Advisors Inc.644$25.0K0.01%

Sold out (25)

Institutions that held REGENXBIO Inc. at the end of Q1 2021 and filed for Q2 2021 without it.